Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/11/2025 | $15.00 | Hold | Jefferies |
| 7/10/2024 | $30.00 | Buy | H.C. Wainwright |
| 4/2/2024 | $30.00 | Buy | Goldman |
| 3/7/2023 | Outperform | Evercore ISI | |
| 3/7/2023 | $39.00 | Buy | BofA Securities |
| 3/7/2023 | $32.00 | Buy | Guggenheim |
| 3/7/2023 | $27.00 | Overweight | Wells Fargo |
| 3/7/2023 | $45.00 | Buy | Stifel |
8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)
144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)
4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
Jefferies initiated coverage of Mineralys Therapeutics with a rating of Hold and set a new price target of $15.00
H.C. Wainwright initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00
Goldman initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00